Early truncal alterations (IDH1/2 mutations, TP53 mutations in astrocytomas, 1p/19q co-deletion in oligodendrogliomas) remain stable across treatment, whereas late-stage alterations show dramatic evolutionary divergence. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).